ADARx Pharmaceuticals, Inc. Common Stock (NASDAQ:ADRX) — Stock Price
ADARx Pharmaceuticals, Inc. Common Stock (NASDAQ:ADRX) is currently trading at $17.78 USD, up 0.59% today. Over the past 52 weeks, shares have ranged between $17.33 and $19.94. This page tracks ADARx Pharmaceuticals, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see ADRX cash flow conversion.
ADARx Pharmaceuticals, Inc. Common Stock (ADRX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ADARx Pharmaceuticals, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
ADARx Pharmaceuticals, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
ADARx Pharmaceuticals, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Total Revenue | $3.45 Million | $0.00 |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Research & Development | $71.51 Million | $43.36 Million |
| SG&A | $20.30 Million | $14.88 Million |
| Total Operating Expenses | $91.81 Million | $58.23 Million |
| Operating Income | $-88.36 Million | $-58.23 Million |
| EBITDA | $-86.04 Million | $-56.73 Million |
| EBIT | $-88.36 Million | $-58.23 Million |
| Interest Expense | — | — |
| Income Before Tax | $-73.09 Million | $-46.36 Million |
| Income Tax Expense | — | — |
| Net Income | $-73.09 Million | $-46.36 Million |
ADARx Pharmaceuticals, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ADARx Pharmaceuticals, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Total Assets | $507.65 Million | $233.45 Million |
| Total Current Assets | $493.38 Million | $225.67 Million |
| Cash & Equivalents | — | — |
| Short-term Investments | $413.48 Million | $205.44 Million |
| Net Receivables | — | — |
| Inventory | — | — |
| Property, Plant & Equipment | — | — |
| Goodwill | — | — |
| Total Liabilities | $709.91 Million | $370.60 Million |
| Total Current Liabilities | $30.48 Million | $8.94 Million |
| Long-term Debt | — | — |
| Net Debt | — | — |
| Total Stockholder Equity | $-202.25 Million | $-137.15 Million |
| Retained Earnings | $-220.70 Million | $-147.61 Million |
ADARx Pharmaceuticals, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ADARx Pharmaceuticals, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow | $262.29 Million | $-48.56 Million |
| Capital Expenditures | $2.94 Million | $455.00K |
| Free Cash Flow | $259.35 Million | $-49.02 Million |
| Investing Cash Flow | — | — |
| Financing Cash Flow | $97.00K | $225.00K |
| Dividends Paid | — | — |
| Stock-Based Compensation | $6.13 Million | $3.95 Million |
| Depreciation | $2.33 Million | $1.50 Million |
| Change in Cash | $52.48 Million | $-8.82 Million |
ADARx Pharmaceuticals, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track ADARx Pharmaceuticals, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for ADARx Pharmaceuticals, Inc. Common Stock.